Zobrazeno 1 - 10
of 816
pro vyhledávání: '"Shinichi KOBAYASHI"'
Autor:
Hitoshi Toyoda, Atsuo Kuramasu, Masahiro Hosonuma, Masakazu Murayama, Yoichiro Narikawa, Junya Isobe, Yuta Baba, Kohei Tajima, Eiji Funayama, Midori Shida, Yuki Maruyama, Aya Sasaki, Yuya Hirasawa, Toshiaki Tsurui, Hirotsugu Ariizumi, Tomoyuki Ishiguro, Risako Suzuki, Sei Kobayashi, Atsushi Horiike, Noriko Hida, Takehiko Sambe, Koji Nobe, Satoshi Wada, Hitome Kobayashi, Mayumi Tsuji, Shinichi Kobayashi, Takuya Tsunoda, Yoshifumi Kudo, Yuji Kiuchi, Kiyoshi Yoshimura
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract Natural killer group 2 member D ligands (NKG2DLs) are expressed as stress response proteins in cancer cells. NKG2DLs induce immune cell activation or tumor escape responses, depending on their expression. Human pancreatic cancer cells, PANC-
Externí odkaz:
https://doaj.org/article/9cc18d13b98e4eae855bec63d4c5642c
Autor:
Nao Imuta, Kosuke Miyai, Motohiro Tsuchiya, Mariko Saito, Takehiro Sone, Shinichi Kobayashi, Sho Ogata, Fumihiko Kimura, Susumu Matsukuma
Publikováno v:
Journal of Pathology and Translational Medicine, Vol 58, Iss 4, Pp 191-197 (2024)
Herein, we report a case of plasmablastic lymphoma (PBL) and diffuse large B-cell lymphoma (DLBCL) that occurred concurrently in the large intestine. An 84-year-old female presented with a palpable rectal tumor and ileocecal tumor observed on imaging
Externí odkaz:
https://doaj.org/article/5e744e0a87e140e18e7bea51f63f8c06
Autor:
Masakazu Murayama, Masahiro Hosonuma, Atsuo Kuramasu, Sei Kobayashi, Akiko Sasaki, Yuta Baba, Yoichiro Narikawa, Hitoshi Toyoda, Junya Isobe, Eiji Funayama, Kohei Tajima, Aya Sasaki, Yuki Maruyama, Yoshitaka Yamazaki, Midori Shida, Kazuyuki Hamada, Yuya Hirasawa, Toshiaki Tsurui, Hirotsugu Ariizumi, Tomoyuki Ishiguro, Risako Suzuki, Ryotaro Ohkuma, Yutaro Kubota, Atsushi Horiike, Takehiko Sambe, Mayumi Tsuji, Satoshi Wada, Shinichi Kobayashi, Toshikazu Shimane, Takuya Tsunoda, Hitome Kobayashi, Yuji Kiuchi, Kiyoshi Yoshimura
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract The low response rate of immune checkpoint inhibitors (ICIs) is a challenge. The efficacy of ICIs is influenced by the tumour microenvironment, which is controlled by the gut microbiota. In particular, intestinal bacteria and their metabolit
Externí odkaz:
https://doaj.org/article/7f87f822bfdf411aabf1cc2f6ca5007b
Autor:
Takashi Shimizu, Eisuke Inoue, Ryotaro Ohkuma, Shinichi Kobayashi, Takuya Tsunoda, Satoshi Wada
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Externí odkaz:
https://doaj.org/article/1afbfe292d48439c963acc6084437cfe
Autor:
Takashi Shimizu, Eisuke Inoue, Ryotaro Ohkuma, Shinichi Kobayashi, Takuya Tsunoda, Satoshi Wada
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionCurrently, first-line immune checkpoint inhibitors (ICIs), including programmed cell death protein-1 (PD-1) inhibitors, are utilized as monotherapy in advanced non-small cell lung cancer (NSCLC) patients with high programmed death ligand-
Externí odkaz:
https://doaj.org/article/79df360ee61b4247bc78ebaffe4da883
Autor:
Ryotaro Ohkuma, Sakiko Miura, Satoshi Muto, Yoshitaka Toyomasu, Yuki Fujimoto, Katsuaki Ieguchi, Nobuyuki Onishi, Takashi Shimizu, Makoto Watanabe, Daisuke Takayanagi, Tsubasa Goshima, Atsushi Horiike, Kazuyuki Hamada, Hirotsugu Ariizumi, Masahiro Shimokawa, Yuya Hirasawa, Tomoyuki Ishiguro, Risako Suzuki, Nana Iriguchi, Toshiaki Tsurui, Emiko Mura, Sachiko Takenoshita, Kazuki Numajiri, Naoyuki Okabe, Kiyoshi Yoshimura, Mayumi Tsuji, Yuji Kiuchi, Toshiki Yajima, Hideyuki Ishida, Hiroyuki Suzuki, Toshiko Yamochi, Shinichi Kobayashi, Takuya Tsunoda, Satoshi Wada
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionProgrammed cell death ligand 1 (PD-L1) expression in tumor tissues is measured as a predictor of the therapeutic efficacy of immune checkpoint inhibitors (ICIs) in many cancer types. PD-L1 expression is evaluated by immunohistochemical st
Externí odkaz:
https://doaj.org/article/ae7a3794a1b04272bd831501907f335c
Autor:
Toshikuni Kawamura, Takaaki Maekawa, Hiraku Ogata, Noriaki Tachi, Shoichiro Kato, Yukiko Osawa, Takahiro Einama, Shinichi Kobayashi, Fumihiko Kimura
Publikováno v:
HemaSphere, Vol 7, p e09951a9 (2023)
Externí odkaz:
https://doaj.org/article/eb0021074b2f4e8dbc3979f6ac39744a
Autor:
Kazuyuki Hamada, Junya Isobe, Kouya Hattori, Masahiro Hosonuma, Yuta Baba, Masakazu Murayama, Yoichiro Narikawa, Hitoshi Toyoda, Eiji Funayama, Kohei Tajima, Midori Shida, Yuya Hirasawa, Toshiaki Tsurui, Hirotsugu Ariizumi, Tomoyuki Ishiguro, Risako Suzuki, Ryotaro Ohkuma, Yutaro Kubota, Takehiko Sambe, Mayumi Tsuji, Satoshi Wada, Yuji Kiuchi, Shinichi Kobayashi, Atsuo Kuramasu, Atsushi Horiike, Yun-Gi Kim, Takuya Tsunoda, Kiyoshi Yoshimura
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionImmune checkpoint inhibitors have had a major impact on cancer treatment. Gut microbiota plays a major role in the cancer microenvironment, affecting treatment response. The gut microbiota is highly individual, and varies with factors, su
Externí odkaz:
https://doaj.org/article/3baf4a74bec646c1a17af2830c7a875b
Autor:
Akinori Sekizawa, Kenichi Hashimoto, Shinichi Kobayashi, Sawako Kozono, Takahiro Kobayashi, Yusuke Kawamura, Motohiro Kimata, Naoya Fujita, Yosuke Ono, Yasuhiro Obuchi, Yuji Tanaka
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
B-cell lymphomas are neoplastic diseases occasionally associated with chronic inflammation. mRNA vaccines for coronavirus disease 2019 (COVID-19) induce inflammatory responses, which often lead to fever and lymphadenopathies indistinguishable from ly
Externí odkaz:
https://doaj.org/article/3fc2de46d90d49b2aec2d6e3b867ac0e
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 18, Iss 1 (2022)
With the Nobel Prize in Physiology or Medicine in 2018, cancer immunotherapy is attracting more attention than ever before and is strongly expected to develop in the future. Immune checkpoint inhibitors were developed as drugs with a completely diffe
Externí odkaz:
https://doaj.org/article/0c530e704b34420e8a2dedbcbe59f0a2